Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 25, 2021

Effect of Ocrelizumab in Blood Leukocytes in Primary Progressive MS

Neurology(R) Neuroimmunology & Neuroinflammation


Additional Info

Disclosure statements are available on the authors' profiles:

Neurology(R) Neuroimmunology & Neuroinflammation
Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS
Neurol Neuroimmunol Neuroinflamm 2021 Jan 06;8(2)e940, JI Fernández-Velasco, J Kuhle, E Monreal, V Meca-Lallana, J Meca-Lallana, G Izquierdo, F Gascón-Giménez, S Sainz de la Maza, PE Walo-Delgado, A Maceski, E Rodríguez-Martín, E Roldán, N Villarrubia, A Saiz, Y Blanco, P Sánchez, E Carreón-Guarnizo, Y Aladro, L Brieva, C Íñiguez, I González-Suárez, LA Rodríguez de Antonio, J Masjuan, L Costa-Frossard, LM Villar

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading